Sabine D. Brookman-May, Professor of Urology at Munchen University, shared a post by UroToday.com on X, adding:
“Excellent coverage on lymph-node-only metastatic urothelial cancer as a distinct entity among complete responders to Nivo/GC.
Med OS in LN-only mUC: 46.3 (Nivo+GC) vs 24.9 months with GC (HR 0.58).”
Quoting UroToday.com’s post:
“Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from CheckMate 901. Presented by Matt Galsky.”
Read further
Sources: Sabine D. Brookman-May/X and UroToday.com/X